की कीमत क्या है Freeline Therapeutics Holdings plc (FRLN)

का मूल्य Freeline Therapeutics Holdings plc (FRLN) है $6.48

का बाजार पूंजीकरण क्या है Freeline Therapeutics Holdings plc (FRLN)

का बाजार पूंजीकरण Freeline Therapeutics Holdings plc (FRLN) है $15.41M

Freeline Therapeutics Holdings plc (FRLN) परिचालन मार्जिन

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

वर्ष	ऑपरेटिंग मार्जिन	परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

वर्ष

ऑपरेटिंग मार्जिन

परिवर्तन

प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

कंपनी	ऑपरेटिंग मार्जिन	ऑपरेटिंग मार्जिन में अंतर	देश
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH
UCB S.A. UCB.BR	31.23%	-	BE

कंपनी

ऑपरेटिंग मार्जिन

ऑपरेटिंग मार्जिन में अंतर

देश